New combo therapy aims to boost lung cancer fight
NCT ID NCT01345851
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This trial is testing a new way to give radiation therapy for people with stage II-III non-small cell lung cancer that cannot be removed with surgery. Instead of standard daily radiation for many weeks, patients receive a shorter, higher-dose course (hypofractionated radiation) along with chemotherapy drugs carboplatin and paclitaxel. The main goal is to find the highest safe radiation dose, while also checking if this approach helps control the tumor and improves survival.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- carboplatin and paclitaxel (chemotherapy drugs) plus hypofractionated radiation therapy
- What this could lead to
- If successful, this approach could offer a more effective and shorter treatment option for people with inoperable lung cancer, potentially improving local tumor control and survival.
- What could go wrong
- This is a small, early-phase trial (29 participants) focused on finding the safest radiation dose, not yet proving effectiveness. Side effects from high-dose radiation and chemotherapy can be significant.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
29 people
The number who actually took part.
- Started
-
Mar 2011
- Expected to finish
-
Jan 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Histologically confirmed primary non-metastatic NSCLC; eligible histological subtypes include: squamous cell carcinoma, adenocarcinoma, squamous-adeno carcinoma, large-cell carcinoma, and non-small cell carcinoma not otherwise specified * Clinical stage II and III NSCLC as defined by American Joint Committee on Cancer (AJCC) Cancer Staging Manual, seventh edition; acceptable imaging modalities to document nodal positivity include computed tomography (CT) chest, positron emission tomography (PET)-CT, or thoracic magnetic resonance imaging (MRI) * For clinically stage II patients, the patient must have been evaluated by a thoracic surgeon, and deemed medically or technically inoperable, or the patient must refuse surgery * Karnofsky performance status \>= 70 * If a woman is of childbearing potential, a negative serum pregnancy test must be documented; women of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; or abstinence) for duration of study treatment and for up to 4 weeks following the study treatment Exclusion Criteria: * Patients who have previously received therapeutic radiation therapy to the chest * Active systemic, pulmonary, or pericardial infection * Use of concurrent gemcitabine-based chemotherapy during radiotherapy * Pregnant women, or women of childbearing potential who are sexually active and not willing/able to use medically acceptable forms of contraception for the entire study period and for up to 4 weeks after the study treatment * Refusal to sign the informed consent * Patients who are participating in a concurrent treatment protocol
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Adenocarcinoma of the lung are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Jonsson Comprehensive Cancer Center
Los Angeles, California, 90095, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an oral drug R01 fight advanced lung, stomach, and esophageal cancers?
- Personalized cancer care: genetic analysis may unlock targeted treatments for advanced lung cancer
- Can an immunotherapy cocktail shrink inoperable lung tumors?
- Blood test could reveal how lung cancer evolves during treatment
- New drug IDP-001 takes on advanced cancers in early trial
- Step counts may predict trouble during lung cancer therapy